Heron Reaffirms 2026 Guidance After Acute Care Revenue Rise Offsets Q1 Sales Drop
Heron Therapeutics’ total product sales declined year-over-year in Q1, while its acute care segment revenue increased on higher hospital utilization. The acute care growth enabled management to reaffirm full-year 2026 revenue guidance despite broader sales headwinds.
1. Q1 Product Sales Decline
Heron’s overall product sales fell in the first quarter as demand softened for its core offerings outside the hospital setting. Lower unit volumes and pricing pressure in certain markets weighed on top-line performance.
2. Acute Care Segment Strength
Revenue from the acute care segment rose, driven by increased hospital adoption of Heron’s formulations for inpatient procedures. This growth in the hospital channel outpaced declines elsewhere, providing a crucial uplift.
3. Full-Year 2026 Outlook Reaffirmed
Despite the Q1 sales headwind, management reiterated its 2026 revenue guidance and maintained prior profitability targets. The company cited sustained momentum in acute care bookings as the key factor supporting its outlook.